CSIMarket
 


Dendreon Corp  (DNDN)
Other Ticker:  
 

Cumulative Dendreon's Working Capital Ratio for Trailing Twelve Months Period

DNDN's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

DNDN Working Capital Ratio for Trailing Twelve Months Period

(Sep 30 2014)
III. Quarter
(Jun 30 2014)
II. Quarter
(Mar 31 2014)
I. Quarter
(Dec 31 2013)
IV. Quarter
(Sep 30 2013)
III. Quarter
Y / Y Current Liabilities Growth -42.64 % -33.57 % 17.24 % -0.17 % 10.42 %
Y / Y Current Assets Growth -29.91 % -33.88 % -38.64 % -41.77 % -38.66 %
Working Capital Ratio for Trailing Twelve Months Period 2.93 2.82 2.86 3.36 3.85
Total Ranking # 1070 # 1072 # 955 # 605 # 211
Seq. Current Liabilities Growth -13.77 % -27.5 % -2.08 % -6.31 % -0.13 %
Seq. Current Assets Growth -5.83 % -9.51 % -7.88 % -10.71 % -11.17 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2014
On the trailing twelve months basis Current Liabilities decreased faster than Dendreon's average Current Assets, this led to increase in in Dendreon's Working Capital Ratio for Trailing Twelve Months Period to 2.93, Working Capital Ratio for Trailing Twelve Months Period remained below Dendreon Corp average.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 23 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Dendreon. While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about DNDN
Working Capital Ratio DNDN in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 24
Sector # 169
S&P 500 # 713


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
5.74 4.15 2.82
(Dec 31 2012)   (Jun 30 2014)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2014, within Biotechnology & Pharmaceuticals Industry Working Capital Ratio for Trailing Twelve Months Period
Curis Inc   7.61 
Fate Therapeutics Inc   7.46 
Aevi Genomic Medicine, Inc.  7.22 
Adma Biologics Inc   6.92 
Compugen Ltd  6.91 
Iovance Biotherapeutics Inc   6.80 
Pharmacyte Biotech Inc   6.71 
Bluebird Bio Inc   6.43 
Sorrento Therapeutics Inc   6.16 
Acorda Therapeutics Inc   6.03 
Armata Pharmaceuticals Inc   5.52 
Viropharma Inc  5.39 
Windtree Therapeutics Inc  5.32 
Nanostring Technologies Inc   5.03 
Brainstorm Cell Therapeutics inc   4.85 
Amgen Inc   4.40 
Palisade Bio Inc   4.29 
Vaxart Inc   4.16 
Cel sci Corporation  4.09 
Seagen Inc   4.09 
Halozyme Therapeutics Inc   4.05 
Gentium S.p.a.  3.96 
Beam Therapeutics Inc   3.71 
Protalix Biotherapeutics inc   3.45 
China Biologic Products Holdings Inc   3.37 
Agenus Inc  3.35 
Telik Inc  3.27 
Cellular Biomedicine Group Inc   3.20 
Ladrx Corporation  3.12 
Dendreon Corp  3.02 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com